ArticleEye (London, England)2012

Comment on 'Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab'.

J H VallancePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.